Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.
LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.
Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.
LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.
The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.
LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.
LivaNova PLC (LIVN) has announced it will release its fourth-quarter and full-year 2024 financial results on Tuesday, February 25, 2025. The company will host a conference call to discuss the results at 1 p.m. London time (8 a.m. Eastern Time) on the same day.
Investors and interested parties can access the audiocast through the company's website at www.livanova.com/events, with recommended login 10 minutes before the start. For telephone access, participants can dial +1 833 470 1428 from the U.S. or +1 929 526 1599 from outside the U.S., using access code 982570. A replay will be available on LivaNova's website for 90 days after the call.
LivaNova (Nasdaq: LIVN) announced publication of two pivotal articles in Brain Stimulation journal regarding the RECOVER clinical study of their VNS Therapy System for treatment-resistant unipolar depression. The study involved 493 adults who had failed over 13 antidepressant treatments on average. While not meeting its primary endpoint, the study showed statistically significant benefits in select secondary endpoints. Active VNS Therapy demonstrated meaningful improvements in quality of life and daily function compared to sham treatment. The study revealed significant benefits in Clinical Global Impression-Improvement (CGI-I) (P=0.004) and Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR) (P=0.049). Three additional manuscripts are planned to report further outcomes.
LivaNova PLC (LIVN) has announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting from December 6-10 in Los Angeles. The company will present multiple scientific posters featuring research on drug-resistant epilepsy treatments, including interim data from their CORE-VNS study.
The presentations will showcase research on VNS Therapy™ applications, including outcomes in children, genetic epilepsy patients, and Lennox-Gastaut Syndrome. Key topics include dosing and titration practices, long-term therapy outcomes, and healthcare services cost comparisons for Medicaid enrollees.
Poster presentations are scheduled for December 7-8, with author presentations from 12:00-2:00 PM PST. Additional displays will be available at the LivaNova Scientific Exhibit on December 9 from 8:00-11:00 AM PST.
LivaNova PLC (Nasdaq: LIVN) has announced its participation in three major healthcare conferences in New York. CEO Vladimir Makatsaria will present business updates through fireside chats at the Stifel Healthcare Conference (November 19, 11:30 AM ET), Wolfe Research Healthcare Conference (November 20, 1:20 PM ET), and Piper Sandler Healthcare Conference (December 3, 10:00 AM ET). All sessions will be livestreamed and available for replay on the company's website.
LivaNova announced successful results from its OSPREY randomized controlled trial for the aura6000 System, an implantable device treating moderate to severe obstructive sleep apnea. The study met its primary safety and efficacy endpoints with statistically significant responder rates between treatment and sham arms. Key secondary endpoints showed impressive results at six months: 66.2% reduction in median apnea-hypopnea index (from 34.3 to 11.6) and 63.3% reduction in oxygen desaturation index (from 34.9 to 12.8). No serious adverse device or procedure-related events were reported. LivaNova plans to submit the data to FDA for premarket approval, with 12-month data expected in first half of 2025.
LivaNova (LIVN) reported strong Q3 2024 results with revenue of $318.1 million, up 11.2% year-over-year. The company's Cardiopulmonary segment revenue increased 15.4% to $172.2 million, while Neuromodulation grew 8.8% to $139.9 million. U.S. GAAP diluted earnings per share reached $0.60, with adjusted EPS at $0.90. Based on strong performance, LivaNova raised its full-year 2024 guidance, now expecting revenue growth between 8.5% and 9.5% on a constant-currency basis, and adjusted EPS of $3.30-$3.40.
LivaNova PLC (Nasdaq: LIVN) has appointed Susan Podlogar to its Board of Directors, effective immediately. Podlogar, who will serve on the Compensation and Human Capital Management Committee, brings 30 years of experience in leading business, talent, and cultural transformations at global companies. Her most recent role was Executive Vice President, Chief Human Resources Officer at MetLife from July 2017 to June 2024. Prior to that, she spent 16 years at Johnson & Johnson in various leadership positions. Podlogar holds an MBA from the University of South Florida and a bachelor's degree from the University of Wisconsin-Parkside.
William Kozy, Chair of the Board, praised Podlogar's visionary leadership and understanding of the global business landscape. With this appointment, the LivaNova Board now consists of 10 Directors.
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, has announced it will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The company will release its Q3 2024 results before the call. Investors and interested parties can access a live audiocast of the call at www.livanova.com/events.
To join the conference call by telephone, participants can dial +1 833 470 1428 from within the U.S. or +1 929 526 1599 from outside the U.S. The access code for the call is 881946. A replay of the call will be available on the LivaNova website for 90 days following the event.
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, has announced that its CEO, Vladimir Makatsaria, will participate in a fireside chat at the Baird 2024 Global Healthcare Conference in New York. The presentation is scheduled for Tuesday, September 10, at 10:15 a.m. Eastern Time.
Interested parties can access the webcast through www.livanova.com/events. Attendees are advised to log on about 10 minutes early to ensure proper setup. A replay of the presentation will be available on the LivaNova website within 24 hours and will remain accessible for 90 days following the event.
LivaNova PLC (Nasdaq: LIVN) reported strong Q2 2024 results, with revenue increasing 8.4% to $318.6 million. Excluding the Advanced Circulatory Support segment wind down, revenue grew 10.8% on a constant-currency basis. U.S. GAAP diluted EPS was $0.30, while adjusted diluted EPS reached $0.93.
The Cardiopulmonary segment saw a 14.5% constant-currency growth, driven by EssenzTM Perfusion System sales. Neuromodulation revenue increased 7.8% on a constant-currency basis. LivaNova raised its full-year 2024 guidance, now expecting revenue growth between 7% and 8% on a constant-currency basis. Adjusted diluted EPS for 2024 is projected to be in the range of $3.10 to $3.20.
FAQ
What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?
What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
On which stock exchange is LivaNova PLC listed?
How many countries does LivaNova operate in?
How many employees does LivaNova PLC have?
What types of products does LivaNova offer?
What significant mergers have shaped LivaNova?
What percentage of LivaNova's revenue comes from the US market?
What recent changes has LivaNova made to its business focus?
How does LivaNova benefit the healthcare industry?
